The role of Janus-activated kinase (JAK) signaling in cell cycle transit and maintenance of genomic stability was determined in HL-60 myeloblastic leukemia cells. Inhibition of JAKs, all JAKs (JAK1, JAK2, JAK3, and tyrosine kinase 2), JAK2, or JAK3, caused a significant reduction in cell growth with a major G 2 -M arrest evident 24 hours after treatment. Targeting all JAKs also caused endoreduplication 48 and 72 hours after treatment. We discovered mitotic cells in both G2 (4N DNA) and G4 (8N DNA) subpopulations of cells treated with an inhibitor of all JAKs as detected by phosphorylated histone H3 expression. Treatment with inhibitors of just JAK2 or JAK3 drastically reduced such mitotic cells. We observed a complete blockage of IFN-; and interleukin-6-induced signal transducer and activator of transcription (STAT)-1 and STAT-3 response when all JAKs were inhibited. At the same time, we found baseline phosphorylated extracellular signalregulated kinase (ERK) 1/2 to be elevated by JAK inhibition, particularly when all JAKs were inhibited. The G 2 -M arrest and endoreduplication induced by JAK inhibitors were reduced in cells pretreated with PD98059 to inhibit ERK. PD98059 also increased back the expression of the MAD2 cell cycle checkpoint protein that was down-regulated during ''all JAKs inhibitor''-mediated endoreduplication. These data suggest that JAK signaling is needed for G 2 -M transit with inhibition of ERK. (Cancer Res 2006; 66(18): 9083-9) 
Introduction
In many cancers, disruption of cell cycle transit and genomic instability are involved in cell transformation. For many tumors, including leukemias, cytokine-regulated signaling through Janusactivated kinases (JAK) is aberrant. The function of such signaling is thus of significant interest in the pathology of cells whose growth and differentiation are governed by cytokines.
JAKs are associated with cytokine and growth factor receptors (1) . Activation of these receptors via ligand binding induces activation of the receptor-associated JAKs through cross-phosphorylation. The tyrosine-phosphorylated sites become docking sites for Src homology 2 domains of signaling proteins. Prominent among these are the signal transducer and activator of transcriptions (STAT). Receptor-recruited STATs are phosphorylated by JAKs, homodimerize or heterodimerize, and rapidly translocate to the nucleus to induce target gene transcription (2) .
Mammals have four members of the JAK family, JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). JAK1, JAK2, and TYK2 are ubiquitously expressed, whereas JAK3 is predominantly expressed in hematopoetic cells and is highly regulated with cell development and activation (3) . A large number of cytokines, such as interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15, and IL-21, are dependent on JAK1 and JAK3. JAK1 is also required for the signaling of receptors that share the gp130 subunit. Those include IL-6, IL-11, oncostatin M, leukemia inhibitory factor, ciliary neurotrophic factor, and granulocyte colony-stimulating factor (CSF). JAK2 is essential for hormone-like cytokines, such as growth hormone, prolactin, erythropoietin, thrombopoietin, as well as cytokines that signal through the IL-3 receptor (IL-3 and IL-5) and granulocytemacrophage CSF. TYK2 is essential for IL-12 signaling (1). The JAK signaling pathways mediate both antiproliferative response following IFN stimulation, which is predominantly mediated by STAT1, and cellular proliferation in response to cytokines and growth factors, which is mediated by STAT3 and STAT5.
Constitutively active STAT3 and STAT5 have been shown in acute myelogenous leukemia (AML), with constitutive activation of STAT3 or STAT5 in 28% and 22% of 36 AML patients, respectively (4) . In addition, constitutive activation of STAT3 was correlated with significantly shorter disease-free survival. Some patient samples, as well as the HL-60 human myeloblastic leukemia cell line used as a model for acute promyelocytic leukemia, show increased basal activities of all, STAT1, STAT3, STAT5, and STAT6 (5) . Constitutive activation of STAT proteins in cancer can be caused by overexpression of growth factor receptors or their ligands, such as IL-6, epithelial growth factor and their receptors, the platelet-derived growth factor receptor, or ERB2. However, excessive JAK kinase activity in tumors is perhaps the most common mechanism for constitutive phosphorylation and activation of STATs (6) .
The JAK/STAT pathways also have a role in cell cycle control as shown by the growth arrest induced by viral infection. Activation of JAK1 and TYK2 by IFN-a can delay G 1 -S to G 2 -M transition (7). However, the role and mechanism of JAKs in cell cycle control are not known. In the current study, we report that intact JAK signaling seems to be essential for proper progression through G 2 -M and for maintaining genomic stability. We also identified extracellular signal-regulated kinase (ERK) 1/2 as a possible mediator for the JAK inhibitor-mediated endoreduplication and down-regulation of the MAD2 G 2 -M checkpoint protein.
inhibitor'' throughout the article), JAK2 inhibitor II, and JAK3 inhibitor VI (Calbiochem, La Jolla, CA) were administered from stock solutions in DMSO with a final concentration of 2, 12.5, and 2 Amol/L, respectively. Concentrations of the all JAKs and the JAK3 inhibitor were chosen as multiples of the in vitro IC 50 as provided by the manufacturer. The concentration for the JAK2 inhibitor was determined by the concentration for maximum inhibition (50 Amol/L) as provided by the manufacturer and decreased to the maximum amount showing no apparent toxicity in our cell system (12.5 Amol/L). ERK inhibitor PD98059 (10 or 20 Amol/L; Sigma) was administered from a stock solution in DMSO 1 hour before treatment with JAK inhibitors. Experimental cultures were initiated at a density of 0.2 Â 10 6 cells/mL and assayed 24, 48, and 72 hours after treatment. Viability was monitored by 0.2% trypan blue (Invitrogen) exclusion and routinely exceeded 95% before drug administration.
Cell cycle and mitosis analysis. Cells (0.5 Â 10 6 ) were collected from cultures, pelleted at 1,000 rpm in a microfuge for 5 minutes, and permeabilized with 1 mL of 90% methanol at À20jC for 20 minutes. Samples were washed 2Â in 1 mL PBS and resuspended in 200 AL PBS containing 5 Ag/mL 4 ¶,6-diamidino-2-phenylindole (DAPI; from a 0.2 mg/mL solution in double-distilled H 2 O, Polysciences, Warrington, PA) and 5 AL allophycocyanin (APC)-conjugated antibodies against Ser 10 phosphorylated histone H3 (pHH3, Cell Signaling, Beverly, MA). Cells were incubated for 1 hour at room temperature and analyzed by flow cytometry. Doublets were identified by a DAPI signal width versus area plot and excluded from analysis. pHH3-positive cells were identified as a subgroup of cells in G2 by a shift in fluorescence intensity in the APC channel. All flow cytometric analyses were done on a BD LSRII flow cytometer (BD Biosciences, San Jose, CA).
STAT activation assay. Cells (0.5 Â 10 6 ) were collected in duplicates and pelleted at 1,000 rpm for 5 minutes. One set of duplicates was resuspended in 500 AL PBS (37jC) containing 0.5% bovine serum albumin (BSA) with 25 ng/mL IFN-g or 40 ng/mL IL-6 ( from a stock solutions in H 2 O; Sigma); the control set was resuspended in 500 AL PBS (37jC) with 0.5% BSA. After incubation for 10 minutes at 37jC, cells were pelleted and fixed by resuspension in 100 AL of 2% paraformaldehyde (Alfa Aesar, Ward Hill, MA) in PBS for 10 minutes. Cells were permeabilized by addition of 900 AL methanol (À20jC) for a final concentration of 90% methanol and kept at À20jC for 20 minutes. Samples were washed 2Â in 1 mL PBS and stained with a staining solution composed of 200 AL PBS with 0.5% BSA, 5 AL APC-conjugated pY701 STAT1 or pY705 STAT3 antibodies [all phosphorylated STAT (pSTAT) antibodies were from BD Biosciences]. Flow cytometric analysis was done following 1 hour of incubation period at room temperature. The fluorescence area signal was divided by the forward angle light scatter area signal to normalize the fluorescence for cell size. The area scale factor was set to place both fluorescence and light scatter signals on scale, and the quotient was normalized to a midscale value to facilitate measurement of shifts due to treatment. Control cells were used to define the so normalized STAT fluorescence histogram representing basal levels of activated STAT (pSTAT) against which the fluorescence histogram for treated cells was compared. A logic gate capturing 95% of the control cells was used to measure the percentage of cells exceeding basal pSTAT in treated populations due to the fluorescence histogram shift.
ERK1/2 phosphorylation assay. Cells (0.5 Â 10 6 ) were collected from cultures and pelleted at 1,000 rpm for 5 minutes, fixed, and permeabilized as described above. Samples were resuspended in 200 AL PBS with 0.5% BSA containing 5 AL APC-conjugated antibody specific for mitogenactivated protein kinase (MAPK) p42/44 dually phosphorylated at Thr 202 and Tyr 204 (Cell Signaling, Danvers, MA). Flow cytometric analysis was done following 1 hour of incubation period. Flow cytometric analysis was done as described for STATs. Fluorescence intensity of control cells was assumed to represent basal levels of phosphorylated ERK (pERK). Logic gates defining the percentage of cells exceeding basal pERK levels were set as for pSTAT by comparing fluorescence histograms of treated cells against that of control cells. Cell populations positive for pERK were arbitrarily set as the highest 5% of control peaks.
Western blotting. Protein was extracted from cells using a 1% SDS lysis buffer. DNA was removed by centrifugation at 13,000 rpm at 4jC for 100 minutes. Protein concentration was determined by measuring the absorbance at 585 nm of proteins in a Bradford assay (Sigma). Protein (15 Ag) was loaded on a 12% Tris-HCl precast gel (Bio-Rad, Hercules, CA). Following electrophoresis at 120 V for 2 hours, protein was electrotransferred onto an Immobilion-P membrane (Millipore, Bedford, MA) for 2 hours at 90 V. Membranes were blocked in 5% nonfat milk in TBS-Tween 20 and probed with MAPK p44/42, h-actin (Cell Signaling, Danvers, MA), or STAT3 pY705 (BD Biosciences), respectively. To detect these probes by enhanced chemiluminescence, horseradish peroxidase-conjugated antirabbit and anti-mouse antibodies were used as secondary antibodies, respectively. Blots were incubated with detection reagents 1 and 2 (Amersham Biosciences, Buckinghamshire, United Kingdom) and visualized using blue-sensitive X-ray film (LPS, Rochester, NY). Blots were stripped and reprobed for h-actin as a loading control.
MAD2 expression. Cells were collected, fixed, and permeabilized as described above. Cells were incubated with 1 AL MAD2 antibody (BioLegend, San Diego, CA) per 200 AL PBS for 1 hour, washed once with PBS, and incubated with a goat anti-rabbit secondary antibody conjugated with R-phycoerythrin (Southern Biotechnology Associates, Birmingham, AL) for 1 hour. MAD2 expression was determined by flow cytometry reading the PE channel. Cells that received secondary antibody only were used to set the threshold for identifying MAD2-positive cells.
Fluorescence microscopy. Cells (0.5 Â 10 6 ) were collected 72 hours after treatment with all JAKs inhibitor or vehicle. Cells were permeabilized in 1 mL of 90% methanol, washed, and stained with DAPI as described above. MAD2 staining was done as described above. Cells were transferred onto a cover slide and visualized using the blue and red excitation filter of the fluorescence microscope (Olympus BX 41, Tokyo, Japan), respectively. Magnification was Â400.
Statistical analysis. Statistical analyses were done with the analysis Toolpak add-in to Microsoft Office Excel 2003. ANOVA analyses were used to test for overall significance within one data set. Paired sample Student's t tests were used to compare two treatment groups at a time. Ps lower than 0.05 in a two-tailed test were considered to be significant.
Results
Inhibition of JAKs reduced cell growth and induced G 2 arrest. The JAK/STAT pathway is implicated in both enhancing cell growth, mediated by STAT3 and STAT5, as well as in suppressing cell growth, mediated by STAT1. Because JAKs can signal through multiple STATs, we determined the effect of JAK inhibition on cell proliferation. Cell cultures were initiated at 0.2 Â 10 6 cells/mL in the absence or presence of JAK inhibitors that targeted either JAK2, JAK3, or all JAKs (JAK1, JAK2, JAK3, and TYK2). At 24, 48, and 72 hours of treatment, cell numbers were determined by hemocytometer counts. All of the JAK inhibitors used dramatically suppressed cell growth when compared with vehicle-treated control cells (Fig. 1A) . Because cells treated with the JAK inhibitors appeared enlarged compared with vehicletreated cells, DNA content was determined by flow cytometric evaluation of DAPI-stained cells. Flow cytometric analysis of DAPI-stained cells revealed a G 2 arrest in cells with JAK2 inhibited and more dramatically in cells with JAK3 inhibited (Fig. 1A) . For JAK3 inhibitor-treated cells, cells in S phase was drastically reduced and cells in G 2 showed greater DNA content than G 2 control cells (data not shown). Inhibiting all JAKs (JAK1, JAK2, JAK3, and TYK2) caused multinucleation as detected by fluorescence microscopy ( Fig. 1B-E) . Flow cytometric DNA histograms showed endoreduplication resulting in a second S phase (S2) and an 8N DNA population (G4) by 24 hours of treatment ( Fig. 2A) . Treatment with 2 Amol/L of all JAKs inhibitor for 24 hours caused an enlarged G2 peak (Fig. 2D) . At 72 hours, endoreduplication resulted in 8N DNA (G4) and 16N DNA (G8) cells (Fig. 2E ). JAKs were thus required for cell growth and cell cycle progression through G 2 -M. Inhibition of all JAKs resulted in failure of cytokinesis with endoreduplication causing 8N (G4) and 16N (G8) DNA subpopulations. Genomic stability thus seems dependent on JAKs.
Effect of JAK inhibitors on mitosis. Because cells treated with the inhibitors of all JAKs did not multiply yet continued growing through endoreduplication, we measured the mitosis marker pHH3 to determine whether endoreduplicating cells continued to undergo mitosis. Figure 3 shows the dual-variable flow cytometric plots (Fig. 3A-D ) of pHH3 versus DNA from which the percentage pHH3 of G2 or G4 subpopulations was calculated (Fig. 3E) . In control cells, 12.5 angle light scatter signal to normalize out any effects of changing cell size. Using control cells, basal levels of STAT1 and STAT3 activation were derived against which treated cells were compared. From the fluorescence histogram from control cells, a gate capturing 95% of cells was defined and the percentage of cells exceeding it was defined as positive cells exceeding basal levels for treated populations. Inhibition of JAK2 or JAK3 alone was not sufficient to suppress STAT1 phosphorylation induced by IFN-g, whereas inhibiting all JAKs resulted in a complete loss in pSTAT1 response to IFN-g (Fig. 4A ) . In addition to the loss of responsiveness to IFN-g, inhibiting all JAKs also resulted in a 19.2% reduction of the mean basal pSTAT1 level (data not shown). JAK inhibition also reduced the effect of IL-6 on STAT3. The all JAKs inhibitor and the JAK3 inhibitor significantly suppressed STAT3 activation by IL-6 (Fig. 4B) . This verifies that the pharmacologic inhibitors used had the anticipated effect of inhibiting STATs and shows the differential dependence of STAT activation on different JAKs. A Western blot of pSTAT3 confirms the flow cytometric data on JAK-dependent activation of STAT3 by IL-6 (Fig. 4C) .
JAK inhibition caused increased levels of pERK. Because JAK/ STAT signaling has been found to be directly connected with both positive and negative regulation of ERK, the effect of JAK inhibition on ERK was determined. Levels of phosphorylated (T202 and Y204) ERK were determined by flow cytometry for control cells and cells treated with inhibitors of all JAKs, JAK2, or JAK3. The percentage of cells exceeding basal levels comparing control and treated populations is reported as for the STATs. Inhibiting all JAKs caused an increase in the flow cytometrically detected pERK compared with basal levels in control cells; 17.2 F 6.57% were now positive. Inhibition of either JAK2 or JAK3 also caused an increase of total pERK to 10.23 F 3.71% and 9 F 3.61% positive, respectively (Fig. 5) . These data suggest an inhibitory effect of JAKs on ERK with increased ERK baseline phosphorylation following JAK inhibition. A Western blot confirms activation of ERK by inhibition of all JAKs (Fig. 5B) . The results are consistent with previously reported negative regulation of ERK by JAK/STAT signaling and motivate interest in its significance to the endoreduplication we observed.
ERK inhibition by PD98059 ameliorated the G 2 arrest and endoreduplication induced by JAK inhibition. To test the significance of the induced ERK activation on the endoreduplication induced by JAK inhibition, we inhibited ERK with PD98059 before inhibiting JAKs. PD98059 is a MAPK/ERK (MEK) inhibitor shown previously to inhibit ERK in these cells (8) . DNA histograms of the control and treated populations after 48 hours are shown in Fig. 6 . When ERK was inhibited by 10 or 20 Amol/L PD98059 1 hour before treatment with JAK inhibitors, the G 2 arrest and endoreduplication mediated by JAK inhibition was reduced in a dosedependent manner (Fig. 6A-L) . In addition, the ERK inhibition normalized signs of aneuploidy, such as the increased DNA content of cells in G 2 following JAK2 inhibition (Fig. 6D , H, and L) and the peaks detected between G1 and G2 and between G2 and G4 in cells treated with the all JAKs inhibitor (Fig. 6B, F, and J) . Hence, ERK activation seems to be mediating the endoreduplication caused by JAK inhibition. The results indicate a role for MAPK signaling in promoting genomic instability.
MAD2 expression is decreased in endoreduplicating cells. To test whether the endoreduplication was associated with changes in cell cycle checkpoint proteins, we determined the expression of G 2 -M regulator MAD2. Cells treated with the all JAKs inhibitor showed decreased levels of the G 2 -M checkpoint protein MAD2 48 hours after treatment (Fig. 7B) . JAK2 or JAK3 inhibition did not cause any detectable change in MAD2 expression (Fig. 7C  and D) paralleling effects on endoreduplication. When ERK was inhibited with PD98059, MAD2 expression was increased in all treatment groups (Fig. 7E-L, N, and P) . This coincided with a decrease in G 2 -M arrest and endoreduplication. JAK inhibition and consequential ERK activation thus seem to down-regulate expression of the G 2 -M checkpoint regulator MAD2, which normally inhibits the APC. When ERK was inhibited by PD98059, MAD2 expression was increased resulting in an inhibition of anaphase and subsequent cytokinesis. This disruption of normal APC regulation may thus contribute to the endoreduplication observed.
Discussion
In summary, we find that inhibition of JAKs, which results in compromised STAT but enhanced ERK activation with decreased expression of the MAD2 G 2 -M checkpoint protein, causes accumulation of G 2 -M cells and subsequent rounds of endoreduplication. Blocking the ERK enhancement prevented the endoreduplication indicating the functional significance of the enhanced ERK activation. The results point to a need for signaling through JAKs to prevent G 2 -M genomic instability and polyploidy.
When JAK2, JAK3, or all JAKs were inhibited, we observed a severe G 2 -M arrest with significant reduction in cell proliferation. The G 2 -M arrest seems to be a sign of a common downstream facilitator. STAT3, for example, was inhibited by all JAKs inhibitors used with the JAK2 inhibitor having the least effect and causing a milder G 2 arrest when compared with the other inhibitors. STAT3 is considered an oncogene after it has been observed to be constitutively active in leukemias and other tumors. STAT3 activation has been identified as promoter of proliferation and cell cycle by regulating expression of cyclin D1, c-myc, Bcl-X, and survivin (9) . Although these molecules are related to G 1 progression, STAT3 can also be linked indirectly to G 2 progression. g-Irradiation-induced G 2 -M arrest could be inhibited by treatment with IL-3 (10). IL-3 has been reported to signal through JAK2 (10) with subsequent STAT3 and STAT5 activation (11) .
STAT1 phosphorylation in response to IFN was completely abolished only when all JAKs were inhibited. STAT1 is generally considered to be growth inhibitory as it induces the classic IFN response genes, such as IFN response factor-1 (IRF-1), which is a mediator of reducing growth and protein synthesis in response to viral infection (12) . It is plausible that the STAT1/IRF-1 pathway could be involved in regulating cell cycle progression, such as preventing mitosis. When all JAKs were inhibited with complete suppression of STAT1, we observed an increase in cells undergoing mitosis as determined by pHH3-positive cells. HH3 becomes Ser 10 and Ser 28 phosphorylated in early stages of mitosis during chromosome condensation initiating early prophase (13) . Hence, early mitotic events appeared to be intact in cells treated with the all JAKs inhibitor; however, cells failed to divide resulting in multiplying nuclei. Whereas we could also detect cells in G4 in cells treated with the JAK3 inhibitor, this treatment caused a significant reduction of cells in M and S phases. A decrease in S phase in response to JAK3 inhibition has also been observed by others and was suggested to be mediated by cyclin D3 down-regulation and p21(WAF1) upregulation (14) .
Polynucleation following inhibition of all JAKs coincided not only with a complete block of STAT1 but also with an increased baseline pERK. A negative cross-talk of STAT1 and ERK has been suggested previously. ERK and STAT1 have been reported to coimmunoprecipitate (15) . The antagonistic behavior of STAT1 and ERK was shown with IFN-a-inducing STAT1 phosphorylation and at the same time decreasing ERK and MEK activation.
Caraglia et al. (3) reported that Ras/ERK signaling could be involved in the protection of tumor cells from apoptosis by IFN-a, also indicating a negative cross-talk between ERK and STAT1. MAPKs have also been reported to interact with STAT3 and STAT5 (16) (17) (18) .
ERK has been implicated in controlling genomic instability. Treatment of HeLa cells with fumarylacetoacetate, a substance causing multinucleation, resulted in sustained activation of ERK. When ERK was inhibited using PD98059, micronuclei with signs of mitotic instability and spindle disturbance were significantly reduced (19) . Another group reported that tyrosine-phosphorylated ERK relocates from the nucleus to the Golgi complex during G 2 and M and is associated with Golgi vesicles in proximity to mitotic spindles (20) .
In our current study, we found an increased expression of the G 2 -M cell cycle checkpoint protein MAD2 following treatment with PD98059, thus indicating that ERK might be involved in driving G 2 -M transition. In fact, in cells treated with the all JAKs inhibitor, elevated ERK levels coincided with decreased expression of MAD2 (Fig. 7B) . The resulting endoreduplication in cells with low levels of MAD2 expression might be linked to the absence of p53 in HL-60 cells used in the current study. Burds et al. (21) reported that cells with deletion in both MAD2 and p53 were extremely vulnerable to chromosomal instability. Loss of p53 as it occurs in many cancer cells, including HL-60 cells, is frequently linked to chromosomal instability by creating a cellular environment that is more forgiving of DNA or chromosomal damage (22) .
To explore the possibility that the endoreduplication following inhibition of all JAKs could be a sign of megakaryocytic differentiation, we measured megakaryocytic cell surface markers CD41, CD62, and van Willebrand factor. All those markers were absent in endoreduplicating HL-60 cells (data not shown). Because HL-60 cells are extremely unlikely to differentiate into megakaryocytes, we also examined K562 cells, which are known for their ability to differentiate into megakaryocytic cells. Although these cells showed similar endoreduplication in response to the all JAKs inhibitor, megakaryocytic cell surface markers were also not expressed (data not shown). 
